









Markets
/
Stocks
/
nasdaq-qgen
/

Qiagen NV

QGEN

50.950USD

-0.280-0.55%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

11.03BMarket Cap

26.20P/E TTM



Qiagen NV

50.950

-0.280-0.55%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Qiagen NV

Currency: USD Updated: 2026-02-06

Key Insights

Qiagen NV's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 18 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 54.16.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Qiagen NV's Score

Industry at a Glance

Industry Ranking

18 / 392

Overall Ranking

108 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Qiagen NV Highlights

StrengthsRisks

Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.09B.

Undervalued

The company’s latest PE is 26.20, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 153.75M shares, decreasing 22.76% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 5.10K shares of this stock.

Analyst Rating

Based on 18 analysts

Hold

Current Rating

54.159

Target Price

+5.72%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Qiagen NV is 9.18, ranking 13 out of 392 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 540.42M, representing a year-over-year increase of 3.69%, while its net profit experienced a year-over-year increase of 22.09%.

Score

Industry at a Glance

Previous score

9.18

Change



Financials

8.43

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.69

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

8.77

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Qiagen NV's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Qiagen NV is 7.22, ranking 149 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is 26.20, which is 390.43% below the recent high of 128.51 and 14.92% above the recent low of 22.29.

Score

Industry at a Glance

Previous score

7.22

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 18/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Qiagen NV is 6.78, ranking 328 out of 392 in the Biotechnology & Medical Research industry. The average price target is 50.00, with a high of 57.00 and a low of 45.00.

Score

Industry at a Glance

Previous score

6.78

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 18 analysts

Hold

Current Rating

54.159

Target Price

+5.72%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Qiagen NV

QGEN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Qiagen NV is 7.42, ranking 73 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 57.15 and the support level at 45.41, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.48

Change

-0.06

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.908

Neutral

RSI(14)

50.813

Neutral

STOCH(KDJ)(9,3,3)

25.270

Neutral

ATR(14)

2.356

Low Volatility

CCI(14)

-122.556

Sell

Williams %R

58.450

Sell

TRIX(12,20)

0.514

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

51.592

Sell

MA10

52.777

Sell

MA20

51.744

Sell

MA50

48.470

Buy

MA100

47.307

Buy

MA200

46.925

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Qiagen NV is 7.00, ranking 86 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 74.64%, representing a quarter-over-quarter decrease of 8.98%. The largest institutional shareholder is The Vanguard, holding a total of 8.86M shares, representing 4.09% of shares outstanding, with 0.73% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Wellington Management Company, LLP

23.33M

-10.35%

BlackRock Institutional Trust Company, N.A.

3.98M

-80.43%

MFS Investment Management

22.91M

-2.43%

The Vanguard Group, Inc.

Star Investors

9.33M

+1.85%

T. Rowe Price International Ltd

7.52M

+26.73%

EARNEST Partners, LLC

4.21M

+0.15%

Amundi Asset Management, SAS

4.15M

+4.30%

Boston Partners

4.02M

+17.37%

BofA Global Research (US)

3.61M

+269.19%

DWS Investment GmbH

4.62M

+39.94%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Qiagen NV is 9.21, ranking 1 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.29. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Qiagen NV’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.